Franklin Berger

Franklin Berger

Director/Board Member at ATEA PHARMACEUTICALS, INC.

Net worth: 9 M $ as of 2026-09-29

76 year
Health Technology
Finance
Consumer Services

Profile

Mr. Franklin M.
Berger
, CFA MBA, is an Independent Director at Retension Pharmaceuticals, Inc., a Lead Independent Director at Atea Pharmaceuticals, Inc., a Senior Advisor at Qiming US Ventures Management, LLC and a Managing Director at FMB Research.
He is on the Board of Directors at Retension Pharmaceuticals, Inc., Satellos Bioscience, Inc., Atea Pharmaceuticals, Inc. and Walking Fish Therapeutics, Inc. Mr. Berger was previously employed as a Lead Independent Director by Rain Oncology, Inc., a Chairman by Proteostasis Therapeutics, Inc., an Independent Director by ESSA Pharma, Inc., an Independent Director by Atreca, Inc., an Independent Director by Tocagen, Inc., an Independent Director by Immune Design Corp., an Independent Director by BioTime, Inc., an Independent Director by Five Prime Therapeutics, Inc., an Independent Director by BELLUS Health, Inc., a Lead Independent Director by Thallion Pharmaceuticals, Inc., a Senior Manager-Portfolio by NEMO Fund, Inc., a Senior Manager-Investment by Sectoral Asset Management, Inc., an Independent Director by Seattle Genetics, Inc., a Managing Director-Equity Research by JPMorgan Securities, Inc., a Managing Director-Equity Research by Salomon Smith Barney, Inc., a Director-Equity Research by Smith Barney Asset Management, a Managing Director-Equity Research by Josephthal, Lyon & Ross, Inc., and an Advisor by Brookline Capital Acquisition Corp.
He also served on the board at Applied Therapeutics, Inc., Kezar Life Sciences, Inc., Emisphere Technologies, Inc., Isotechnika Pharma, Inc., Isotechnika, Inc., VaxGen, Inc., Alzheon, Inc., Asterias Biotherapeutics, Inc., Aurinia Pharmaceuticals, Inc., Caprion Proteomics, Inc., CellCarta Biosciences, Inc., Episcopal Relief & Development Corp., HealthShares, Inc., iTherX Pharmaceuticals, Inc., The Genetics Co., Inc. and ViroChem Pharma, Inc.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-08-17 690,067 ( 3.25% ) 6 M $ 2026-09-29
2026-06-17 536,097 ( 0.67% ) 3 M $ 2026-09-29
0.27%
2026-10-12 22,517 ( 0.27% ) 237 104 $ 2026-09-29

Franklin Berger active positions

CompaniesPositionStart
ATEA PHARMACEUTICALS, INC. Director/Board Member 2019-08-31
SATELLOS BIOSCIENCE INC. Director/Board Member 2023-06-28
Chief Executive Officer 2005-05-31
Consultant / Advisor 2018-12-31
Director/Board Member -

Former positions of Franklin Berger

CompaniesPositionEnd
KEZAR LIFE SCIENCES, INC. Director/Board Member 2026-05-10
ESSA PHARMA INC. Director/Board Member 2025-10-08
ATRECA, INC. Director/Board Member 2024-05-12
RAIN ONCOLOGY INC. Director/Board Member 2024-01-24
░░░░░░ ░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
See the detail of Franklin Berger's experience

Education of Franklin Berger

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

65

1st degree connections

41

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies41

Health Technology

Health Technology

Distribution Services

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Finance

Finance

Consumer Services

Health Technology

Miscellaneous

Health Technology

Commercial Services

Health Technology

Health Services

Health Technology

Finance

Health Technology

Commercial Services

NEMO Fund, Inc.

Health Technology

Health Technology

Consumer Services

Health Technology

Miscellaneous

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Finance

Health Technology

  1. Stock Market
  2. Insiders
  3. Franklin Berger